Alcon AG at JPMorgan Healthcare Conference Transcript
Good afternoon, everybody. I'm David Adlington, head the European Med-Tech Research Team for JPMorgan in London. It's my pleasure to introduce David Endicott, CEO of Alcon. There will be Q&A afterwards. Please wait for the microphone for questions. But David, over to you. Thank you very much.
Well, thank you, and good afternoon. We are excited to be here and start another year kicking off with JPM. It's fun to be back and talk about a lot of things that we've been working on.
As most of you know, we have a broad portfolio of stuff and a broad kind of source of growth. And I think when you look at the surgical market or you look at the vision care market, you can see kind of steady mid-single-digit growth across the portfolio of markets in which we play, which is underpinned by a whole bunch of fundamental positives like aging demographics, comorbidity, the need for eye care
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
